Title Category Credit Event date Cost
Blood/Marrow Transplant for Autoimmune Disease
  • Transplantation
  • Disease Management
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionAutoimmune diseases are caused by an overactive immune system that targets the patient’s own cells. Most individuals with autoimmune disorders respond to conventional drug therapies; however, conventional drug therapies are not curative. Although not all autoimmune diseases can be treated with a blood/marrow transplant (BMT), the primary concept underlying use of a BMT for these diseases is that ablating and “resetting” the immune system can alter the disease process.
Updates on Heart Failure Management
  • Transplantation
  • Disease Management
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionInnovations in Left Ventricular Assist Devices (LVADs) for End-stage Heart Failure
Non-HLA Barriers to Blood/Marrow Transplant
  • Transplantation
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - Ethics
$0.00 Activity descriptionHistorically, the lack of finding a human leukocyte antigens (HLA)-match has been perceived as the largest barrier to blood/marrow transplantation (BMT). Many barriers besides a lack of suitably matched donors exist and can have an adverse impact on access and outcomes of BMT. This session will identify key barriers to BMT including barriers that prevent access to care, such as language and cultural differences; illiteracy; and environmental, geographic, genetic, and medical barriers.
Hepatocellular Carcinoma: Treatment Options Outside of Transplant
  • Transplantation
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionLiver transplantation (LT) is considered the best curative treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) within Milan criteria. Several therapeutic procedures have been proposed as bridging treatments for individuals with HCC awaiting LT. The choice of each treatment is based on: the characteristics of the patient; liver function; comorbidities; and on the number, dimensions, and localization of HCC.
New Allocation Systems and Policy Changes for Liver Transplantation
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionAllocation of liver donor organs in the United States is a complex and evolving process. New allocation/distribution systems are in development that attempt to more accurately allocate organs. This session will address the major paradigm shifts that are underway to improve the equitable allocation of livers for individuals waiting for a liver transplant. Policy changes addressing geographic disparities without compromising outcomes will also be discussed.Provided byThis activity is provided by OptumHealth Education.
Lung-in-a-Box: Advances in Lung Transplant Technology
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionFor individuals with severe lung disease, a lung transplant is an effective treatment. New advances in lung transplant technology have extended the life of a lung once it has been removed from the donor’s body. This session will discuss the advances in lung transplant technology that aim to increase the supply of donor lungs and maximize transplant outcomes.Provided byThis activity is provided by OptumHealth Education.Commercial supportNo commercial support was received for this activity.
Normothermic Liver Preservation: Current Status and Future Directions
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionLiver transplantation is severely limited by the shortage of donor organs and, in addition, many potential donor organs cannot be used because suboptimal livers do not tolerate conventional cold storage. Normothermic machine perfusion (NMP) is an emerging technology that has the potential to transform liver preservation and the field of transplantation. This presentation will discuss the role of NMP as a tool to assess graft viability and its potential impact on liver transplant waiting list mortality.
Pediatric Blood/Marrow Transplant Overview
  • Transplantation
  • Pediatrics
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionA blood/marrow transplant (BMT) is a treatment for children with certain types of cancer or other diseases. The goal of BMT is to treat or cure disease, which can include various types of pediatric cancers, disorders of the blood and immune system, and a wide variety of other rare disorders and syndromes. This session will highlight the different sources for blood/marrow transplants and discuss the indications, risks, benefits, and outcomes.Provided byThis activity is provided by OptumHealth Education.
Psychosocial Evaluation of Adult Cardiothoracic Transplant Candidates and Candidates for Long-term Mechanical Circulatory Support
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionThe psychosocial evaluation is well-recognized as an important component of the multifaceted assessment process to determine candidacy for cardiothoracic transplantation and long-term mechanical circulatory support. Due to the lack of a consensus-based set of recommendations for psychosocial assessment during the evaluation, a committee composed of international experts representing the International Society for Heart and Lung Transplantation (ISHLT) and collaborating societies was formed.
Acute Myelogenous Leukemia: New Therapies after 40 Years!
  • Transplantation
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionAML is one of the most aggressive cancers. While other cancers have benefited from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. With improved biologic understanding of AML and the incorporation of genetic prognostic markers and novel therapeutic options bringing new advancements to the field, individuals with AML have reason to hope. This session will review recent advances and new agents that have been approved for the treatment of AML and discuss the role of biomarkers in AML treatment decisions.

Pages